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 ABSTRACT 
 
 
Previous studies have shown that tumor-endothelial markers (TEMs) are up-
regulated in immunosuppressive, pro-angiogenic dendritic cells (DCs) found in tumor 
microenvironments. We reported that pro-angiogenic monocyte-derived DCs (Mo-
DCs), utilized for therapeutic vaccination of cancer patients upon maturation, 
markedly differ in their ability to up-regulate tumor-endothelial marker 8 (TEM8) gene 
expression. A DC vaccination trial of 17 advanced cancer patients (13 melanoma and 
4 renal cell carcinoma), carried out at the Cancer Institute of Romagna (I.R.S.T.) in 
Meldola, highlighted a significant correlation between delayed-type hypersensitivity 
test (DTH) and overall survival (OS). In the study, relative TEM8 mRNA and protein 
expression levels (mature (m) vs. immature (i) DCs), in DCs obtained for therapeutic 
vaccines were evaluated by quantitative real-time RT-PCR and cytofluorimetric 
analysis, respectively. mDCs from six healthy donors were included for comparison 
purposes. Eight non-progressing patients, all DTH-positive, had a mean fold increase 
(mfi) of 1.97 in TEM8 expression. Similarly, a TEM8 mRNA mfi = 2.7 was found in 
healthy donor mDCs. Conversely, mDCs from nine progressing patients, all but one 
with negative DTH, had a TEM8 mRNA mfi of 12.88. Thus, mDC TEM8 expression 
levels would seem to identify (p = 0.0018) patients who could benefit from DC 
therapeutic vaccination. 
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1. INTRODUCTION 
 
 
Cancer is a complex disease initiated by a series of cumulative genetic and 
epigenetic changes that occur in normal cells. However in addition to the malignant 
cell itself, cancer is a disease of microenvironment and immunity. Although genetic 
and epigenetic alterations drive cellular transformation, genomic plasticity, and 
evolution, it has become increasingly apparent that multiple signals delivered within 
the tumor microenvironment by modifier genes, stromal, endothelial cells, and 
immune cells are critical factors in determining the progression vs. dormancy or 
destruction of an initiated lesion and also whether metastasis may occur. 
 
Immune disregulation / immunosuppression in cancer patients is a composite event 
in which tumor-derived factor conditions not only peripheral immune niches but also 
the bone marrow and other hematopoietic organs (mouse spleen), leading to 
abnormal myelopoiesis and accumulation of immunosuppressive myelomonocytic 
cells at the tumor site. Disregulation / immunosuppression is therefore likely to occur 
at two separate sites: locally at tumor-host interface, where tumor directly conditions 
the tumor stroma, and systematically, where an expanded pool of immature and 
immunosuppressive myeloid cells are free to circulate and mediate suppression in 
lymphoid organs and in the blood. 
 
 
1.1 CANCER IMMUNOTHERAPY 
Cancer immunotherapy attempts to harness the exquisite power and specificity of the 
immune system for the treatment of malignancy. Although cancer cells are less 
immunogenic than pathogens, the immune system is clearly capable of recognizing 
and eliminating tumor cells. However, tumors frequently interfere with the 
development and function of immune responses. Thus, the challenge of the 
immunotherapy is to be in advance in the cellular and molecular immunology in order 
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to develop strategies that effectively and safely augment antitumor responses 
(Blattman J.N. el al. 2004). 
 
The term immunotherapy refers to any approach that seeks to mobilize or manipulate 
the immune system of a patient for therapeutic benefit (Steinman R.M. et al. 2004). In 
this regard, there are numerous strategies to improve the patient's resistance to 
cancer. These include non-specific activation of the immune system with microbial 
components or cytokines, antigen-specific adoptive immunotherapy with antibodies 
and/or T cells, and antigen-specific active immunotherapy (that is, vaccination). 
 
Therefore, such in vivo or direct vaccination approaches, although simple, cost 
effective, and broadly applicable, have not been effective in the setting of cancer 
(Livingston P.O. 1989). What is likely to contribute to such failures is that the 
vaccines against infectious agents are administered prophylactically to healthy 
individuals as a protective measure against future exposures, whereas the cancer 
vaccines are administered therapeutically in the cancer patient in the face of pre-
existing antigenic load (the tumor). Other factors contributing to limit the efficacy of 
early cancer vaccination protocols include the need to stimulate the cellular arm of 
the immune response and the fact that immune responses are suppressed in cancer 
patients. Such failures underscore the need to develop increasingly more potent 
cancer vaccination strategies (Gilboa E. 2004). 
 
 
1.2 ANTI-CANCER STRATEGIES 
The immune system can respond to cancer cells in two ways: by reacting against 
tumor-specific antigens (molecules that are unique to cancer cells) or against tumor-
associated antigens (molecules that are expressed differently by cancer cells and 
normal cells). 
 
The identification of defined tumor antigens in humans (Boon T. et al. 1994; 
Rosenberg S.A. 1997) prompted the development of adoptive T-cell therapy. Yet, the 
most attractive strategy is vaccination, which is expected to induce both therapeutic 
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T-cell immunity (in the form of tumor-specific effectors T cells) and protective T-cell 
immunity (in the form of tumor-specific memory T cells that can control tumor 
relapse) (Pardol D.M. 1998; Gilboa E. 1999; Finn O.J. 2003). 
 
Efficient antigen presentation and T-cell priming are essential components of 
effective antitumor immunity and the dendritic cells are critical to both of these 
functions. 
 
One approach that is gaining increasing popularity among tumor immunologists, is to 
immunize cancer patients with autologous, patient derived DCs loaded with tumor 
antigens ex vivo. The underlying premise of this approach is that the efficiency and 
control provided by ex vivo manipulation of the DCs generates an optimally activated 
APC and a superior method for stimulating immunity in vivo if compared with more 
traditional vaccination methods. 
 
This approach to the therapeutic vaccination of individuals who have cancer relies on 
random encounter of the vaccine with host DCs. A lack of encounter of the vaccine 
antigen with DCs might result in the absence of an immune response. Alternatively, 
an inappropriate encounter - for example, with inactivated DCs or with the ‘wrong’ 
subset of DCs - might lead to silencing of the immune response (Steinman R.M. et al. 
2003). 
 
We do not know how tumor antigens need to be delivered to DCs in vivo to elicit an 
appropriate immune response (Merad M., et al., 2002; Banchereau J. et al., 2005). 
 
 
1.3 IMMUNOSUBVERSION: THE ACTIVE SUPPRESSION OF THE 
IMMUNE RESPONSE 
In humans, tumors develop a series of strategies to evade immunosurveillance, and 
these strategies are presumably unrelated to the other characteristics of 
carcinogenesis and result from the selective pressure exerted by the immune 
system; these strategies are known as immunoselection. 
 4 
 
Several tumor products that are dispensable for cell-intrinsic cancer-cell 
characteristics might be involved in immunosubversion: that is, the active 
suppression of the immune response. For example, tryptophan degradation by 
indoleamine 2,3-dioxigenase (IDO), which is constitutively expressed by human 
tumors (particularly by prostate, colon and pancreatic carcinomas, but also by 
interdigitating DCs), promotes resistance to immune mediated rejection of the tumor 
cells (Uyttenhove C. et al. 2003). Locally produced IDO can block the proliferation of 
CD8+ T cells at the tumor site (Uyttenhove C. et al. 2003), as well as it can promote 
the apoptosis of CD4+ T cells (Terness P. et al. 2002). 
 
The exact molecular mechanisms by which tumors mediate immunosubversion are 
the subject of intense investigation. One possible explanation of how tumors subvert 
the immune response is to consider that the tumors are ‘false’ lymphoid organs; 
therefore, T-cell priming in the tumor microenvironment is defective as a result of the 
presence of dysfunctional or tolerogenic antigen-presenting cells (Zou W. 2005). 
Indeed, tumor beds contain various factors (such as VEGF, IL-6, IL-10, TGFβ, 
macrophage colony-stimulating factor (M-CSF), NOS2, arginase-1, IDO, PGE2, 
COX2 and gangliosides) that can inhibit the differentiation, maturation and function of 
DCs (Zou W. 2005). Accordingly, local DCs tend to mediate immunosuppressive, 
rather than immunostimulatory, effects and to promote the TReg-cell differentiation 
(Ghiringhelli F. et al. 2005). 
Another possible explanation for tumor-mediated immunosubversion is based on a 
quantitative argument. Tumor characteristics that are immunostimulatory in small 
tumors can become immunosuppressive in large tumors. 
 
It seems that there are numerous ways by which tumor cells can evade or ‘paralyze’ 
immunosurveillance. However, it remains an open question which of these multiple 
mechanisms affects oncogenesis and cancer progression in humans. 
Of note, in some cases, it is possible that, although an immune response to tumors is 
mounted, this response fails to eliminate the tumors or could even stimulate 
carcinogenesis and tumor progression, as a result of chronic inflammation. 
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1.3.1 IDO: enzyme indoleamine 2,3-dioxygenase that is upregulated in human 
DCs upon in vitro maturation 
Immunological strategies to fight cancer have demonstrated less clinical efficacy than 
anticipated. Several factors contribute to this status quo, including immune escape 
mechanisms of tumors or the limited immunogenicity of the antigen delivery systems 
(Steinbrink K. et al. 1999). 
 
One potential mechanism, leading to immunological tolerance, is the recently 
recognized immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO) 
(Uyttenhove C. et al., 2003). IDO is a heme-containing enzyme which catalyses the 
initial, rate limiting-step in the degradation of the essential amino acid tryptophan into 
distinct kynurenine metabolites (Grohmann U., et al., 2003). The depletion of 
tryptophan renders T-cells more susceptible to apoptosis (Lee G.K., et al., 2002). 
Moreover, various tryptophan downstream metabolites, e.g. kynurenine and 
quinolinate, are by themselves directly toxic for T-cells (Terness P., et al., 2002). 
IDO-expressing, tolerizing antigen presenting cells (APCs) are furthermore supposed 
to induce regulatory T-cells (Tregs) (Faunce D.E., et al., 2004). 
 
Clinically relevant immunoregulatory functions of IDO include the protection from 
intracellular pathogens (Gupta S.L., et al., 1994), the maintenance of maternal 
tolerance towards the fetus during pregnancy (Munn D.H., et al., 1998), the 
suppression of T-cell responses to MHC-mismatched allografts (Bauer DM., et al., 
2005), the protection from autoimmune diseases (Sakurai K., et al., 2002), and – 
most important – the tumor resistance to cytotoxic CD8+ T-lymphocytes. (Munn D.H., 
et al., 2004; Harlin H., et al., 2006). In this respect, IDO is expressed by two 
complementary constituents both in the tumor microenvironment as well as in the 
regional draining lymph nodes: the malignant cells themselves and the subset of 
APCs (Lee J.H., et al., 2005). Thereby, both local and systemic tolerance to 
neoplastic cells may be generated and maintained. 
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IDO-expression in APCs and its complex modulation by various cytokines and direct 
cellular interactions may become an issue for DC-based vaccine therapies. Indeed, 
previous reports have demonstrated that functional IDO is induced upon in vitro 
generation of mature DCs. (Braun D., et al., 2005; Bergwelt-Baildon MS., et al., 
2006). 
 
We analyzed IDO expression, its activity as well as its in vitro relevance in the 
patients receiving DC-based vaccinations. 
 
 
1.4 DENDRITIC CELLS (DCs) 
Dendritic cells (DCs) are professional antigen presenting cells (APCs) in the immune 
system, which are able to induce primary T cell responses. Because of their central 
role in the initiation of immune responses, DCs are an important tool for tumor 
antigen specific immunotherapy of cancer. 
 
Immature DCs are present in peripheral tissues, where they possess the capacity to 
take up and process antigen into small peptides; in absence of inflammation, DCs 
remain in an immature state, and antigens are presented to T cells in the lymph node 
without co-stimulation, leading to either the deletion of T cells or the generation of 
inducible regulatory T cells. 
 
The tissue inflammation induces the maturation of DCs and their migration to 
draining lymph nodes for presentation to resting lymphocytes. The mature DCs 
express high levels of cell-surface major histocompatibility complex (MHC) antigen 
complexes and co-stimulatory molecules. This allows the priming of CD4+ T helper 
cells and CD8+ cytotoxic T lymphocytes (CTLs), the activation of B cells and the 
initiation of an adaptive immune response. It is now known that activated CD4+ T-
helper cells up regulate CD40 ligand, and that signaling through the CD40 receptor 
fully activates DCs. 
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Therefore DCs-based vaccines are now being explored in the clinic. So far, most 
DCs vaccines have been used to stimulate immune responses, in particular the ones 
which can combat the cancer. Recent findings indicate that whereas mature DCs 
induce immunity, immature or semi-mature DCs can cause immunological tolerance, 
opening up application in transplantation and autoimmunity (Figdor C.G., et al., 
2004). 
 
In every case, effective migration of DCs to secondary lymphoid organs is essential 
for the DCs to exert their immune regulatory effect. 
 
 
1.4.1 DCs-based vaccines 
Multiple factors contribute to the failure of DCs in priming effective antitumor 
responses in tumor-bearing hosts: the low number of DCs available in the tumor site, 
poor access of DCs to tumor antigen, the limited capacity of tumor cells to activate 
intra-tumoral DCs, and secretion by the tumor cells of factors that inhibit DCs 
maturation. 
Administration of DCs generated and loaded with tumor antigens ex vivo, can be 
used to circumvent tumor immunotolerance and thus as therapeutic cancer vaccines 
(Fong L. et al., 2000). 
A variety of preparations of DCs can stimulate antitumor immunity, including DCs 
loaded with proteins, DCs fused with tumor cells, and DCs transduced with tumor-
derived RNA or viral vectors. At present, all these approaches rely on ex vivo 
manipulation of isolated DCs to produce the vaccine. 
DCs vaccination has been facilitated by the development of methods to generate 
DCs either from rare, but proliferating, CD34+ precursors or from common, but mostly 
non-proliferating, CD14+ monocytes (so-called monocyte-derived DCs) (Banchereau 
J., et al., 2001). 
Although early clinical trials have indicated that DCs vaccines can induce anti-tumor 
immune responses in some cancer patients, there is still much to be learned 
regarding the subtype, maturation and activation status of DCs, antigen loading, 
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route of administration, the dose and timing interval, and migration of DCs-based 
vaccines. 
 
 
 
1.4.2 DCs migration 
The migration to secondary lymphoid organs is essential for the DCs to exert their 
immune regulatory effect. 
DCs migration is a complex process that involves a coordinate activation of different 
classes of effectors molecules: chemokines, adhesion molecules, as well as matrix 
metalloproteinase’s (MMPs) and lipid mediators. 
DCs maturation results in the down regulation of chemokine receptors associated 
with tissue retention, whereas CCR7 and CD62L are up regulated (Dieu M.C. et al., 
1998). 
The expression of CCR7 on mature DCs and on naïve and central memory T cells is 
essential for their coordinate migration to the T-cell area of draining lymph nodes 
because this migration is guided by CCL19 and CCL21, the two ligands for CCR7. 
Both chemokines, are expressed by stromal cells in the T-cell area of secondary 
lymphoid organs (Scandella E. et al., 2004). 
Recently, it was observed that the maturation-induced up-regulation of CCR7 
expression on human monocyte-derived DCs was insufficient to allow MoDCs 
migration to CCL19 and CCL21 (Scandella E. et al., 2002; Luft T. et al., 2002). 
Human MoDCs matured either with soluble CD40L or with Poly I:C markedly 
enhanced surface expression of CCR7 but they were not at all or they were only 
poorly responsive to CCL19 and CCL21. Interestingly, MoDCs migration to CCL19 
and CCL21 was readily observed on maturation in the presence of the inflammatory 
mediator prostaglandin E2 (PGE2), though PGE2 did not change the expression level 
of CCR7 on mature MoDCs, providing evidence for an alternative effect of PGE2 
(Scandella E. et al., 2004). 
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1.4.3 DCs maturation 
Ex vivo expanded DCs are currently applied as autologous cellular vaccines for 
advanced cancer patients (Fong L. et al. 2000). Most commonly, patients monocytes-
derived immature DCs (iDCs) are generated in the presence of granulocytes-
macrophage colony stimulating factor (GM-CSF) and IL-4, loaded with tumor 
antigens, and exposed to inflammatory signals (i. e., LPS, CD40L, or double-
stranded RNA and/or prostaglandins) to induce final maturation. This simple 
procedure yields a homogeneous population of DCs that resemble interstitial DCs. 
 
It is not clear which maturation stimulus is best for the induction of tumor-specific T 
cells in vivo; however, the most commonly used maturation protocol for Mo-DCs 
consists of four reagents, TNFα, IL-1β, IL-6 (three inflammatory cytokines) and PGE2, 
also known as monocyte-conditioned media mimic, or cytokine cocktail (CYC) 
(Jonuleit H. et al. 1997). 
 
Pro- and anti-angiogenic molecules can emanate from cancer cells, endothelial cells, 
stromal cells, blood and the extracellular matrix. Their relative contribution is likely to 
change with type, site and tumor growth. 
The balance between pro- and anti-inflammatory signals that are present in 
microenvironments determines the phenotype and the behavior of the immune cells 
at the site of inflammation. While DCs activated by pro-inflammatory signals (e.g. 
LPS and TNF-α) are characterized by pro inflammatory functions, the exposure of 
DCs to anti-inflammatory molecules such as IL-10, IL-4 and PGE2 induces alternative 
programs of activation characterized by peculiar membrane phenotype and function. 
 
At the same manner, it is the balance between pro- and anti-inflammatory molecules 
of the maturation cocktail to determine the angiogenic and migratory programs in 
activated MoDCs and the release of important cytokines subset that regulate the 
nature and the efficacy of immune responses. 
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1.4.4 PGE2 
Prostaglandin E2 (PGE2) is a common inflammatory mediator known to exert Th2-
promoting and IL-12-antagonistic activity via several distinct mechanisms, affecting 
both APCs and Th cells. 
 
The rational to include PGE2 in the maturation cocktail is to endow the ex vivo-
generated DCs with the capacity to migrate to draining lymph-nods and to enhance T 
cell priming (Scandella E. et al. 2002; Luft T. et al. 2002). 
 
Therefore, in the context of the tumor microenvironment, PGE2 can mediate Th2 
polarization and promote the differentiation of DCs secreting the immunosoppressive 
cytokine IL-10 (Morelli A.E. et al. 2003). Several studies have shown that PGE2 may 
induce mDCs with counterproductive immunosuppressive / proangiogenic features 
(Gilboa E. 2007; Sinha P. et al. 2007). 
 
The key negative impact of PGE2 on the function of ex vivo-generated DCs is 
probably that PGE2 abolishes both the responsiveness of mature DCs to stimulation 
thought CD40 and their ability to synthesize IL-12 when they reach the lymph node 
and encounter cognate T cells (Luft T. et al. 2002). Additionally, cytokine cocktail-
matured DCs were very effective, even more than immature DCs, at expanding a 
population of immunosoppressive Tregs expressing the forkhead box transcription 
factor FOXP3 (Banerjee D.K. et al. 2006). 
 
Notwithstanding the limitation, the results from published trials (Morelli A.E. et al. 
2003) showed that when treated with PGE2-matured DC vaccines, subsets of 
patients developed clinical responses that occasionally correlated with antigen-
specific immunoresponses. 
 
Hence, on the basis of in vitro results, it is possible to construct arguments both for 
and against the inclusion of PGE2 in the maturation cocktail, but it appears extremely 
difficult to predict whether the presence of PGE2 during the DC maturation will 
increase or decrease the efficacy of the DC-based anticancer therapy in vivo. 
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1.5 PROANGIOGENIC PHENOTYPE OF DCs 
The ability of tumors to compromise the phenotype and function of DC isolated from 
peripheral blood of patients has been described. In contrast, we known much less 
about tumor-associated changes in “in vitro” generated DCs. How DC vaccines are 
altered compared with similar DC from healthy donors still remains an open (often 
overlooked) question. 
 
Indeed, one of the main problems in current experimental trials is the advanced stage 
(IV) of cancer patients. At this stage, progressing tumors often subvert physiological 
myelopoiesis, leading to the expansion of heterogeneous populations of 
dysfunctional monocytes which, may not only help tumors immune-escape, but also 
aid in the construction of new blood vessels for tumor growth (MacLean K. et al 2008; 
Curiel T.J. et al. 2004; Priebe A. et al. 2008). However, it remains unclear whether 
the cells are acting directly or represent precursor cells. Of interest, dendritic cell 
precursors in the tumor microenvironment are reported to assume a mixed DC - 
endothelial cell phenotype to promote angiogenesis (Albini A. et al., 2005). The 
possibility that these cells, named vascular DC (VDC), could incorporate into tumor-
blood vessels has been also reported. Consistently with this observation, an 
increasing number of tumor endothelial markers (TEMs 1 - 9), originally uncovered 
as genes specifically expressed or significantly up-regulated in tumor versus normal 
blood vessels, (St. Croix B. et al., 2000) has been found to be expressed in vascular 
and perivascular leukocytes populations in tumor microenvironment (Gottgried E. et 
al. 2007). 
 
 
1.6 TEM8: MARKER IN PROANGIOGENIC PROGRAMS 
We recently reported that (Venanzi F.M. et al. 2006) PGE2-matured DCs (PGE2-
mDCs) from cancer patients, utilized for autologous therapeutic vaccination, while 
acquiring pro-angiogenic (VEGF-releasing) potential, markedly differ in their ability to 
up-regulate tumor-endothelial marker 8 (TEM8) gene expression (Gabrielli F. 2007). 
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Tumor endothelial marker (TEM8) was uncovered as a gene expressed 
predominantly in the tumor endothelium. Elevated levels of TEM8 in tumor 
microvessels appear to correlate with disease progression in breast and colorectal 
cancer (Davies G. et al. 2004; Rmali K.A. et al. 2005). Of interest, the gene product 
of TEM8 was recently identified as the receptor of the anthrax toxin (ATRX1/TEM8). 
(Carson-Walter E.B., et al., 2001; Bradley K.A., et al., 2003; Whittaker C.A., et al., 
2002). 
 
The expression pattern of TEM8 was especially interesting in that it is the only 
human TEM characterized that shows undetectable mRNA expression in healing 
wounds and corpus luteum tissue, suggesting that this gene may be highly specific to 
tumor angiogenesis and not required for normal adult angiogenesis (St Croix et al. 
2000). 
 
However, TEM8 RNA is also expressed in a small proportion of the endothelial cells 
in normal brain, heart, intestines lung, skeletal muscle and pancreas, and at high 
levels in the endothelial cells of murine fetal liver and brain (St Croix et al. 2000, 
Carson-Walter E.B., et al. 2001). 
 
TEM8 encodes a type I transmembrane protein, 564 amino acids in length. The 
intracellular domain is 220 amino acids in length and the extra cellular region (aa 1-
318) contains a vWFA domain (aa 44-205) also known as an I-domain when it is 
present in integrins (Dickeson S.K., et al., 1998). Three different, apparently 
alternatively spliced, versions of the TEM8 gene have been described. The TEM8 
variants share the same amino-terminal extra cellular part but differ in length and 
sequence in their putative cytosolic regions. Splice variant 1 (SV1) is the longest and 
is the original TEM8 cDNA that encodes a 564 amino acid protein with a long proline-
rich cytoplasmic tail. Splice variant 2 (SV2) encodes a 368 amino acid protein with a 
short cytoplasmic tail. Splice variant 3 (SV3) encodes a protein that is identical to the 
other two throughout most of the extra cellular domain but diverges just before the 
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transmembrane region so that it does not contain a recognizable membrane 
anchoring sequence. 
 
Interest in TEM8 variant 2 increased when it was identified as ATR, a cellular 
receptor for anthrax protective antigen (Bradley K.A. et al., 2001). ATR that is 
identical to TEM8 for the first 364 amino acids, includes the entire extracellular and 
transmembrane domains, and then it terminates after a 4 amino acid divergence from 
TEM8. 
 
Anthrax toxin, the major virulence factor produced by Bacillus anthracis, consists of 
three polypeptides called protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa), 
and edema factor (EF, 89 kDa) (Leppla S.H. et al., 1999; Smith H. et al., 1962). The 
protective antigen mediates the binding of the complex to TEM8 variant 2 (Bradley 
K.A., et al., 2001) whereas lethal factor and edema factor are responsible for eliciting 
toxicity. 
 
The identification of TEM8 as the anthrax receptor helped to clarify a potent 
antitumor response that had been previously obtained with anthrax toxin (Duesbery 
N.S. et al., 2001). Injection of the toxin into tumor-bearing mice led to a strong anti-
tumor response, in some cases causing complete tumor regression. Although the 
mechanism responsible was unclear at the time, an unexpected anti-angiogenic 
effect was postulated to be involved owing to the small number of vessels observed 
in the treated tumors. 
 
TEM8 interacts with the C5 domain of collagen α3 (VI), one of a limited number of 
transcripts preferentially expressed in tumor endothelium among the analyzed 32,500 
total transcripts (St. Croix B., et al., 2000). The interaction of these proteins and their 
coordinate expression in tumor endothelial cells suggests a functional role in 
angiogenesis. 
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The large cytoplasmic tail of both the human and mouse TEM8 proteins share at 
least seven potential phosphorylation sites, supporting the hypothesis that TEM8 is 
involved in transmitting signals into the cells. 
 
Recently, capillary morphogenesis protein 2 (CMG2), the closest homologue to 
TEM8, was identified as a second receptor for anthrax toxin (ATRX2) (Scobie H.M., 
et al., 2003). CMG2 sharing 51% amino acid identity with ATR/TEM8 in the I domain 
was identified originally in a screen for genes differentially regulated during capillary 
induction in vitro. The CMG2 transcript was found to be up regulated early during the 
process of capillary morphogenesis (Bell S.E., et al., 2001), and the CMG2 protein 
was shown to bind to at least two extra cellular matrix (ECM) components, collagen 
IV and laminin. The sub cellular localization of CMG2 was determined to be 
predominantly in the endoplasmic reticulum. This finding suggests that CMG2 may 
be involved in the assembly of the basement membrane matrix that is produced 
during new blood vessel formation. 
 
The mRNA expression profile of ATR/TEM8 as well as mRNA expression and 
binding data of the highly similar protein, CMG2, suggest that one of the 
physiological roles of ATR/TEM8s may be in angiogenesis. However, the presence of 
ATR/TEM8 on the cell surface of most cell types tested in culture, on the tumor 
stroma as well as its presence on macrophages, indicates that there may be 
additional roles for this protein, perhaps in cellular adhesion. 
 
Many of the molecular mechanisms that mediate the relationship between 
inflammation, innate immunity and cancer progression remain to be defined. 
Tumor cells may usurp signaling molecules (i.e. integrins, chemokines and their 
receptors) by which innate immune system interfaces with cancers, for invasion, 
migration and metastasis (Muller A., et al., 2001). 
 
Although TEM8 transcripts have been found to be selectively up regulated in tumor 
angiogenesis, the analyses of TEM8 expression profiles and bioinformatics suggest 
that this presumptive tumor-specific endothelial marker gene may be highly specific 
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in different cell types (like DCs and tumor cells) involved in extra cellular matrix-
remodeling and migration processes, such those observed in inflammatory reactions 
and tumor progression (Novatchkova M. and Eisenhaber F., 2001). 
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2. AIM OF THE STUDY 
 
 
Advanced tumors subvert expansion and differentiation of myelomonocytes cells 
leading to dysfunctional DCs. Previous studies have shown that tumor endothelial 
markers (TEMs) are up regulated in proangiogenic DCs found in tumor 
microenvironment. 
 
Goal of this study is to provide evidence that monocytes-derived DCs from patients 
with advanced cancer, up-regulate TEM8 gene / protein expression. Specifically: 
 
Aim 1. Compare the expression patterns of TEM8 and CMG2 (as judged by 
Quantitative real time RT-PCR and cytofluorimetric assays) of DCs obtained from 
both cancer patients and healthy individuals. 
 
 
Aim 2. Evaluate whether and how TEM8 expression levels in DCs utilized for 
therapeutic vaccination of melanoma and renal cell cancer patients, are related to 
clinical outcome. 
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3. MATERIAL AND METHODS 
 
 
3.1 Patients 
The case series consisted of the 17 patients that had undergone DCs phase I/II 
vaccination trial (2001-2005) for advanced melanoma (n=13) and renal cell 
carcinoma (RCC; n = 4) (Ridolfi R. et al. 2006). (See Tab. I). 
In this trial, 8 patients were scored as responders, and 9 as non-responders 
according to RACIST criteria, and it was observed a positive correlation between 
delayed-type hypersensitivity test (DTH) for tumor lysate (TL) and/or keyhole limpet 
hemocyanin (KLH) and overall survival (see Tab. II). The clinical trial, was approved 
by the Italian Ministry of Health and by the Ethical Committee of Forlì Health and 
Social Services (Azienda ASL-Forlì, Italy). All patients gave the written informed 
consent. 
 
 
3.2 Human cancer cell line 
Different cancer cell lines were obtained from American Type Culture Collection 
(ATCC): HeLa (ATCC Catalog. Number: CCL-248); MDA-MB-231 (ATCC Catalog. 
Number: HTB-26); SkBr3 (ATCC Catalog. Number: HTB-30); ZR75-1 (ATCC 
Catalog. Number: CRL-1500). The cell lines were maintained at 37°C in a humidified 
5% CO2 environment in Dulbecco’s modified Eagles medium (D-MEM) (Cambrex) 
with 1% L-glutamine, 1% penicillin/streptomycin, supplemented (growing condition) 
or not (starving condition) with 10% foetal bovine serum (FBS) (Cambrex). 
The cells were trypsinized and used for the proteic lysate or the RNA extraction. 
 
 
3.3 DCs generation 
Mature DCs from each patient were regenerated from cryopreserved peripheral 
blood monocytes (PBMCs), previously obtained by leukapheresis (5 – 9 litres of 
blood were processed in each collection), without previous mobilization. 
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mDCs obtained from six unrelated healthy donors were included for comparison. 
PBMC were purified on Ficoll-Plaque, and incubated in tissue culture flasks with 
CellGro DC Medium (Cell Genix, Freiburg, Germany) at 10 x 106 cells/ml for 2 h. 
The non-adherent cells were discarded and the adherent cells were incubated in 
CellGro DC Medium containing 1000 IU/ml rhIL-4 (Cell Genix) and 1000 IU/ml rhGM-
CSF (Shering Plough, Milan, Italy) for 7 days to generate a DCs-enriched cell 
population. On day 7, they were defined as iDCs. After eliminating the previous 
culture medium, iDCs were cultured for a further 2 days with a cocktail of cytokines 
(TNF-α, IL-1β, IL-6, Endogen, Pierce Biotechnology, Rockford, USA, PGE2, Cayman 
Chemical, Ann Arbor, MI, USA). Alternatively, iDCs were cultured with the PGE2-
depleted cocktail or with TNF-α, IL-1β, IL-6 and Poly I:C (Amersham Biosciences). 
On day 9 they were defined as mDCs. 
 
 
3.4 Flow cytometry 
iDCs and mDCs phenotypes were determined by single or two-color fluorescence 
analysis. 3–5·105 cells were suspended in 100 µl of buffer (PBS, 2% FCS, 1% 
sodium azide) and incubated for 30 min. at 4°C with 10 µl of appropriate fluorescein 
isothiocyanate or phycoerythrin-labeled monoclonal antibodies (mAbs). The cells 
were then washed twice and resuspended in 500 µl of PBS. The fluorescence was 
analyzed by a FACS Vantage flow cytometer (Becton Dickinson, Milan, Italy). mAbs 
specific for human CD1a, CD14, CD80, CD86, CD11c, CD33, DR (Becton 
Dickinson), CD83 (Immunotech, Marseille, France) and CCR7 (BD Pharmingen, 
Milan, Italy) were used. 
TEM8 protein expression was determined by flow cytometry analysis. Briefly, 5·105 
cells were incubated for 2 hours at room temperature in the dark with 10 µl of the 
primary antibody, 0.5 µg Rabbit polyclonal to TEM8 (abCam, ab21270). The cells 
were then washed 3-times and resuspended in ice cold PBS. The fluorochrome-
labeled secondary antibody (Goat polyclonal to Rabbit IgG-FITC (ab6717) was 
diluted at 1/50 in 3% BSA/PBS and added to cells that were incubated for 30 minutes 
at room temperature in the dark. After three washing the cells were analyzed by a 
FACS CANTO flow cytometer (Becton Dickinson, Milan, Italy). 
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3.5 ELISA assay 
At each pre-set time (24h – 48h), the supernatants of iDCs and mDCs were collected 
and stored at -80°C until analysis was carried out using commercially available 
Endogen Human VEGF Elisa Kit (Pierce Biotechnology) to measure the production of 
VEGF165 and VEGF121 isoforms, according to the manufacture's protocols. 
The quantitative measurement of Trombospondin-1 in culture supernatants was 
carried out using ChemiKine Human TSP-1 EIA kit (Product # CYT 168, Chemicon 
International. 
 
 
3.6 RNA isolation and complementary DNA synthesis 
Total RNA was isolated from monocytes, immature and mature (with standard 
cocktail, PGE2-depleted cocktail or cocktail + Poly I:C) human MoDCs, obtained from 
patients, healthy donors, and breast cancer cells lines. 
The cells (5x105) were lysed by incubation with a lyses buffer that immediately 
inactivates RNase and creates appropriate binding conditions which favour 
adsorption of RNA to the silica membrane. Contaminating DNA is removed by a 
DNase I solution which is directly applied onto the silica membrane during the 
preparation. Simple washing steps with two different buffers remove salts, 
metabolites and macromolecular cellular components. Pure RNA is eluted under low 
ionic strength conditions with RNase-free water. 
The concentration of RNA was determined spectrophotometrically by measuring 
absorbance at 260 nm and RNA integrity was confirmed by electrophoresis on a 
1.2% agarose gel. 
 
We used 1 µg of total RNA for synthesis of first-strand complementary DNA (cDNA) 
by RevertAid H Minus First Strand cDNA Syntesis Kit (Fermentas, Life Sciences). 
The RNA (1 µg) was incubated with H2O and 1µl of Oligo dT Primer (0.5µg/µl) for 5 
minutes at 70°C. At the reaction, 2 µl of 10x Reaction Buffer, the RNAsi inhibitor and 
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2µl of 10nM dNTPs mix were added. The reaction mixture was heated to 37°C for 5 
minutes. 
At the reaction was then added 1µl of the RevertAid H Minus M-MuLV Reverse 
Transcriptase (200u/µl) (final volume 20 µl) and incubated for 60 minutes at 42°C. 
The reaction was heated to 70°C for 10 minutes to inactivate Reverse Transcriptase. 
The resulting cDNA was used for qualitative reverse-transcription polymerase chain 
reaction (RT-PCR) and for quantitative Real-Time PCR. 
 
 
3.7 Qualitative RT-PCR 
One µl of reverse-transcription reactions of iDCs and standard cocktail, PGE2-
depleted cocktail or cocktail + Poly I:C treated-mDCs was used as target in a PCR 
reaction to amplify the IDO. 
 
Primers used: 
IDO FW: CCAAgAACTTgCAgCTgAAg 
IDO RV: TgggTCTATTCCgTTgTgTC 
 
One µl of reverse-transcription reactions of the monocytes and dendritic cells was 
then used as target in a PCR reaction to amplify either a portion of extra cellular 
domain of human TEM8 (AF279145) (200 bp fragment) or a portion of the extra 
cellular domain of human capillary morphogenesis protein 2 (AY233452) (200 bp 
fragment). 
The TEM8 and CMG2 transmembrane domains are indicated in blue. 
 
 
Primers used: 
TEM8: 
FW: TgAAgATCTCTTTTTCTATTCAgAgAgggA 
Rev: TTgATAATCACAgTgCAgCAgAgggg 
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CDS TEM8: 144...1838 
 
                144 atggcca cggcggagcg gagagccctc ggcatcggct 
      181 tccagtggct ctctttggcc actctggtgc tcatctgcgc cgggcaaggg ggacgcaggg 
      241 aggatggggg tccagcctgc tacggcggat ttgacctgta cttcattttg gacaaatcag 
      301 gaagtgtgct gcaccactgg aatgaaatct attactttgt ggaacagttg gctcacaaat 
      361 tcatcagccc acagttgaga atgtccttta ttgttttctc cacccgagga acaaccttaa 
      421 tgaaactgac agaagacaga gaacaaatcc gtcaaggcct agaagaactc cagaaagttc 
      481 tgccaggagg agacacttac atgcatgaag gatttgaaag ggccagtgag cagatttatt 
      541 atgaaaacag acaagggtac aggacagcca gcgtcatcat tgctttgact gatggagaac 
      601 tccatgaaga tctctttttc tattcagaga gggaggctaa taggtctcga gatcttggtg 
      661 caattgttta ctgtgttggt gtgaaagatt tcaatgagac acagctggcc cggattgcgg 
      721 acagtaagga tcatgtgttt cccgtgaatg acggctttca ggctctgcaa ggcatcatcc 
      781 actcaatttt gaagaagtcc tgcatcgaaa ttctagcagc tgaaccatcc accatatgtg 
      841 caggagagtc atttcaagtt gtcgtgagag gaaacggctt ccgacatgcc cgcaacgtgg 
      901 acagggtcct ctgcagcttc aagatcaatg actcggtcac actcaatgag aagccctttt 
      961 ctgtggaaga tacttattta ctgtgtccag cgcctatctt aaaagaagtt ggcatgaaag 
     1021 ctgcactcca ggtcagcatg aacgatggcc tctcttttat ctccagttct gtcatcatca 
     1081 ccaccacaca ctgttctgac ggttccatcc tggccatcgc cctgctgatc ctgttcctgc  
     1141 tcctagccct ggctctcctc tggtggttct ggcccctctg ctgcactgtg attatcaagg 
     1201 aggtccctcc accccctgcc gaggagagtg aggaagaaga tgatgatggt ctgcctaaga 
     1261 aaaagtggcc aacggtagac gcctcttatt atggtgggag aggcgttgga ggcattaaaa 
     1321 gaatggaggt tcgttgggga gaaaagggct ccacagaaga aggtgctaag ttggaaaagg 
     1381 caaagaatgc aagagtcaag atgccggagc aggaatatga attccctgag ccgcgaaatc 
     1441 tcaacaacaa tatgcgtcgg ccttcttccc cccggaagtg gtactctcca atcaagggaa 
     1501 aactcgatgc cttgtgggtc ctactgagga aaggatatga tcgtgtgtct gtgatgcgtc 
     1561 cacagccagg agacacgggg cgctgcatca acttcaccag ggtcaagaac aaccagccag 
     1621 ccaagtaccc actcaacaac gcctaccaca cctcctcgcc gcctcctgcc cccatctaca 
     1681 ctcccccacc tcctgcgccc cactgccctc ccccgccccc cagcgcccct acccctccca 
     1741 tcccgtcccc accttccacc cttccccctc ctccccaggc tccacctccc aacagggcac 
     1801 ctcctccctc ccgccctcct ccaaggcctt ctgtctag  
      
 
Primers used: 
CMG2: 
FW: gTgTTTATTgTgTTggTgTCCTTg 
Rev: gACAATCTgAAATTCCTCCCC 
 
 
CDS CMG2: 4...1470 
 
 1 aggatggtgg cggagcggtc cccggcccgc agccccggga gctggctgtt ccccgggctg 
       61 tggctgttgg tgctcagcgg tcccgggggg ctgctgcgcg cccaggagca gccctcctgc 
      121 agaagagcct ttgatctcta cttcgtcctg gacaagtctg ggagtgtggc aaataactgg 
      181 attgaaattt ataatttcgt acagcaactt gcggagagat ttgtgagccc tgaaatgaga 
      241 ttatctttca ttgtgttttc ttctcaagca actattattt tgccattaac tggagacaga 
      301 ggcaaaatca gtaaaggctt ggaggattta aaacgtgtta gtccagtagg agagacatat 
      361 atccatgaag gactaaagct agcgaatgaa caaattcaga aagcaggagg cttgaaaacc 
      421 tccagtatca taattgctct gacagatggc aagttggacg gtctggtgcc atcatatgca 
      481 gagaaagagg caaagatatc caggtcactt ggggctagtg tttattgtgt tggtgtcctt 
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      541 gattttgaac aagcacagct tgaaagaatt gctgattcca aggagcaagt tttccctgtc 
      601 aaaggtggat ttcaggctct taaaggaata attaattcta tactagctca gtcatgtact 
      661 gaaatcctag aattgcagcc ctcaagtgtc tgtgtggggg aggaatttca gattgtctta 
      721 agtggaagag gattcatgct gggcagtcgg aatggcagtg ttctctgcac ttacactgta 
      781 aatgaaacat atacaacgag tgtaaaacca gtaagtgtac agcttaattc tatgctttgt 
      841 cctgcaccta tcctgaataa agctggagaa actcttgatg tttcagtgag ctttaatgga 
      901 ggaaaatctg tcatttcagg atcattaatt gtcacagcca cagaatgttc taacgggatc 
      961 gcagccatca ttgttatttt ggtgttactg ctactcctgg ggatcggttt gatgtggtgg 
     1021 ttttggcccc tttgctgcaa agtggttatt aaggatcctc caccaccacc cccccctgca 
     1081 ccaaaagagg aggaagaaga acctttgcct actaaaaagt ggccaactgt ggatgcttcc 
     1141 tattatggtg gtcgaggggt tggaggaatt aaaagaatgg aggttcgttg gggtgataaa 
     1201 ggatctactg aggaaggtgc aaggctagag aaagccaaaa atgctgtggt gaagattcct 
     1261 gaagaaacag aggaacccat caggcctaga ccacctcgac ccaaacccac acaccagcct 
     1321 cctcagacaa aatggtacac cccaattaag ggtcgtcttg atgctctctg ggctttgttg 
     1381 aggcggcagt atgaccgggt ttctttgatg cgacctcagg aaggagatga ggtttgtata 
     1441 tgggaatgta ttgagaaaga gctaactgct 
 
 
The PCR conditions were an initial denaturation at 95°C for 5 minutes, 35 cycles at 
95°C for 1 minute, 63°C for 1 minute (to amplify extra cellular hTEM8), 60°C for 1 
minute (to amplify hCMG2 and IDO), 72°C for 1 minute and then, after 35 cycles, 10 
minutes of incubation at 72ºC. PCR reactions were performed using a thermal cycler 
(Biorad). Identical PCR condition were used for TEM8 expression in breast cancer 
cells except the selection of 24 cycles. 
 
The PCR products were separated by horizontal gel electrophoresis in 1.2% 
agarose/ethidium bromide (10mg/ml). PCR products were run for approximately 60 
minutes at 90 volts, visualised using a UV transilluminator (Biorad) and 
photographed. 
 
As internal control to assess the integrity of the different RNAs and to confirm the 
success of the reverse-transcription reaction, primers for housekeeping gene 
GAPDH (glyceraldehyde phosphate dehydrogenase) were used in the reaction of 
amplification. 
 
The primers used are: 
Fw GAPDH: CAACAgCgACACCCACTCCT 
Rev GAPDH: AggCCATgTgggCCATgA 
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3.8 DNA sequencing 
To confirm the specific amplification of the extracellular and transmembrane domain 
of human TEM8 and the portion of the extra cellular domain of human capillary 
morphogenesis protein 2, DNA sequencing was performed on PCR products from 
each different sample monocytes, iDCs and mDCs. The PCR bands were excised 
from the agarose gel, purified with Macherey-Nagel gel extraction columns and 
sequenced in both orientations. The sequencing reactions were carried out by MWG 
Biotech/M-Medical (Germany). 
 
 
3.9 Quantitative Real-Time PCR 
One µl of reverse-transcription reactions of monocytes, iDCs and standard cocktail or 
cocktail + Poly I:C treated-mDCs was used as target in a Quantitative Real Time 
PCR. 
Real-time RT-PCR was performed by means of the MX3000P Real-time PCR system 
(Stratagene) and the BRILLIANT SYB Green QPCR Master mix according to the 
protocol provided by the manufacturer. After initial denaturation for 10 minutes at 
95°C, thermal cycling was performed for 40 cycles with steps of 94°C for 48 seconds, 
60°C for TEM8, CMG2 and IDO, for 48 seconds, and 72°C for 48 seconds, with the 
fluorescence being read at the end of each cycle. 
The same set of primers for TEM8 and CMG2 utilized in Qualitative RT-PCR reaction 
were used for the Quantitative PCR. 
 
The analysis was performed with MxPro QPCR Software version 3.00 for MX3000P. 
The obtained values were within the linear range of a standard curve and were 
normalized to yield the same amount of glyceraldehyde phosphate dehydrogenase 
(GAPDH) messenger RNA (mRNA) (Fw GAPDH: CAACAgCgACACCCACTCCT and 
Rev GAPDH: AggCCATgTgggCCATgA). All PCR products were analyzed by 
determination of melting profiles as well as by agarose gel electrophoresis. 
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4. RESULTS 
 
 
4.1 PHENOTYPE ANALYSIS OF REGENERATED DCs 
Two maturation cocktails, consisting of either TNF-α, IL-1β, IL-6 and PGE2 or TNF-α, 
IL-1β, IL-6 and Poly I:C, were evaluated for the ability to induce phenotypic changes 
associated with maturation in regenerated DCs from melanoma and renal carcinoma 
patients. As detailed in Materials & Methods section, iDCs and mDCs were analyzed 
by single or two-color fluorescence analysis; the fluorescence was measured by a 
FACS Vantage flow cytometer, using a panel of monoclonal antibodies to detect 
CD1a, CD14, CD11c, CD33, CD80, CD86, DR, CD83, and CCR7 antigens. The data 
about iDCs and mDCs markers are reported in Table III and Figure 1. 
Of note, similar expression patterns of DC antigens are obtained from healthy 
donors. 
 
As expected the fraction of mDCs expressing CD1a+ and CD14+ antigens, markers 
for Langerhans cells and monocytes respectively, was low (3%), while 80% of mDCs 
showed a myeloid phenotype (either/both CD11c+ or/and CD33+ expression) (data 
not shown). 
 
Although both TNF-α, IL-1β, IL-6 and PGE2 and TNF-α, IL-1β, IL-6 and Poly I:C, 
maturation cocktails increased the fraction of cells expressing HLA-DR, CD80, CD86 
and CD83 (molecules that are necessary to activate T cells in vivo), a considerable 
difference between the cocktails was observed. Indeed, while DCs treated with TNF-
α, IL-1β, IL-6 + PGE2 showed a significant expression of the chemokine receptor 
CCR-7, (Table III), while TNF-α, IL-1β, IL-6 + Poly I:C treatment was not (data not 
shown). 
 
The finding suggests that the lack of CCR-7 up-regulation during maturation with 
Poly I:C might be the consequence of the fact that prostaglandin E2 is a major 
inducer of this receptor (Scandella E. et al., 2002). It should be stressed that 
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regenerated mDCs did not differ substantially from those originally utilized for 
vaccination, in terms of phenotype cell yield, and viability (results not shown). 
 
 
4.2 PROANGIOGENIC POTENTIAL OF REGENERATED DC 
VACCINES 
Recently, human myeloid dendritic cells matured with LPS in the presence of anti-
inflammatory molecules such as IL-10 or PGE2 (LPS+IL-10 or LPS+PGE2), have 
been reported as able to selectively secrete the potent angiogenic cytokine vascular 
endothelial growth factor (VEGF-A) in vitro and to possess proangiogenic activity in 
vivo (Riboldi E. et al., 2005). 
Consequently, we evaluated the pro-angiogenic potential of regenerated CKT-PGE2 
matured DCs measuring (ELISA assay) the levels of VEGF-A in different culture 
media: IL-1β, IL-6, TNF-α and PGE2;  IL-1β, IL-6 and TNF-α; LPS and PGE2; and IL-
1β, IL-6, TNF-α and Poly I:C. 
 
As shown in Figure 2, VEGF-A production (both VEGF-A isoforms 165 and 121 are 
recognized by antibodies) was selectively observed in the supernatants of DCs 
matured in presence of either CKT+PGE2 or LPS+PGE2. Conversely, VEGF-A 
production was strongly reduced following DCs maturation with PGE2-depleted 
cocktail. Likewise, basal levels of VEGF-A were observed in DCs activated at the 
presence of Poly I:C. Although it has been reported that, IL-10 or PGE2 treatments of 
monocytes-derived DCs may stimulate the production of the potent anti-angiogenetic 
factor Trombospondin I (TPS-I), we observed not production of TPS-I in the 
supernatant of CKT+PGE2 matured DCs. 
 
Collectively these results suggest that the balance between pro- and antiangiogenic 
activities of DCs may favor the angiogenesis when CKT+PGE2 is used as a 
maturation stimulus. Thus, DCs seem to display an "alternative / type 2" state of 
activation which likely associated with a type 2-polarized immune response known to 
be responsible for the inhibition of inflammatory cytokines, the promotion of tissue 
remodeling and repair, the inhibition of Th1 responses (Mantovani A. et al., 2002). 
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4.3 TEM8 AND CMG2 GENE EXPRESSION IN MYELOID DCs 
Possible modulation of TEM8 and CMG2 expression in the passage from immature 
to mature DCs, have not been previously reported. In order to address this question, 
we initially evaluated by conventional RT-PCR analysis the difference in relative 
mRNA expression levels of TEM8 and CMG2 in PEG2-mDC versus iDC obtained 
from both cancer patients and healthy donors. 
 
Some representative results are summarized in Figure 3. While CMG2 gene is 
widely expressed in immature DCs and in PEG2 matured DCs obtained either from 
cancer patients (Fig. 3.A, n = 8) or healthy donors (Fig. 3.B, n = 3), TEM8 
expression is much more restricted: undetectable or barely detectable in immature 
DCs generated from the same groups of subjects. However, we observed that TEM8 
transcripts were clearly detected in some PGE2-mDC from cancer patients but not in 
all examined PEG2-mDC from healthy donors. 
 
As control, TEM8 transcripts were detected in TEM8-positive HeLa (Premanandan C. 
et al. 2006) and MDA-MB-231 invasive breast cancer cells, but not in TEM8-negative 
SK-BR3 and ZR75-1 breast cancer cells lines (Venanzi F.M. et al. 2006) (Fig. 3.C). 
 
To quantify the difference in relative expression levels during the process of DC 
differentiation, we determined the expression ration of both anthrax receptors from 
both cancer patients and healthy donors by Quantitative Real Time-PCR (Q-RT-
PCR; SYBR-Green based) assays, by utilizing the same sets of primers that were 
used in Standard RT-PCR assay. Overall, the TEM8 and CMG2 real-time RT-PCR 
data parallel standard RT-PCR results. 
Indeed, the quantization of the relative mRNA expression levels between CMG2 and 
TEM8 indicated that the CMG2 transcripts were always preferentially expressed over 
TEM8 transcripts in all DCs and monocyte precursors that had been examined 
(Figure 4). The most obvious difference in the expression ratio of the two genes is 
seen for iDCs. 
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As shown in Figure 5, moderate to comparable increased levels of CMG2 mRNA 
were observed following iDC maturation in both groups of subjects (mean fold 
increase [mfi] = 2.88 vs. 1.95 for patients and healthy donors, respectively). On the 
other hand, a significant difference was found between patients and healthy donors 
([mfi] = 8.4 vs 2.7, respectively; p = 0.015), when evaluating the effect of PGE2 on 
TEM8 mRNA expression. In agreement with findings by other authors (Xu Q. et al., 
2007), mRNA levels of CMG2 transcripts always exceeded those of TEM8 in all 
types of examined cells (Fig. 5). The most important difference in the expression 
ratio of the two genes was seen for iDCs. 
 
We also proceed to investigate the regulation of TEM8 mRNA expression by different 
stimuli. As in the case of VEGF-A production, TEM8 expression was strongly down 
regulated either in mDC matured with the PGE2-depleted cocktail, or by replacement 
of PGE2 with Poly I:C in the cocktail. However, at variance of VEGF–A, the 
LPS+PGE2 maturation of patients DCs did not influence TEM8 or CMG2 basal 
expression (Figure 6). From these data we can deduce that VEGF-A production and 
TEM8 expression might be not subject to the same mechanism of regulation. Thus, 
TEM8 up regulation is not simply a direct consequence of PGE2 in the maturation 
cocktail, but depends on the presence of inflammatory cytokines. 
 
 
4.4 CORRELATION OF TEM8 GENE EXPRESSION WITH CLINICAL 
RESPONSES 
As mDCs from cancer patients displayed high inter-individual variability in TEM8 
expression, we retrospectively checked over a possible correlation between TEM8 
gene expression and the clinical course of the disease. In order to minimize bias due 
to differences in follow-up times, clinical outcome (as detailed in Table II), was only 
divided in two categories: progressive (PD) and not progressive (NP) disease 
(including complete response CR, partial response PR, or stable disease SD (> 6 
months), as defined in previous studies) (Ridolfi R. et al. 2006). An inverse 
relationship was observed between TEM8 mRNA levels and both clinical and 
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immunological responses (Figure 7). Indeed, eight NP patients (including 2 CR, 1 
PR and 5 SD), all DTH-positive (5 for both TL and KLH, 3 for KLH only; median OS = 
32 months) showed low levels of TEM 8 mRNA expression ([mfi] = 1.97) similar to 
healthy donors ([mfi] = 2.7). Conversely, mDC from nine PD patients, all but one 
negative DTH (median OS = 5 months), showed high TEM8 mRNA expression levels 
([mfi] = 12.88). Additionally, mDCs from both PD and NP patients displayed similar 
(moderate) levels of CMG" expression ([mfi] = 2.88 vs. 3.2, respectively) close to 
those of healthy donors ([mfi] = 1.95). 
 
Finally, cytofluorimetric data for TEM8 protein expression in mDCs from PD and NP 
patients paralleled TEM8 mRNA results. As an example, Figure 8 shows that, more 
than 97% of mDC and 30.5% iDC from PD patients (TEM8 mRNA mDC vs. iDC; mfi 
= 30) expressed TEM8 protein, wherease TEM8 protein was expressed in 41% of 
iDC and 23% of mDC from NP patients (TEM8 mRNA mDC vs. iDC; mfi = 2.70). 
 
We conclude that in our study, high TEM8 expression levels in DC vaccine 
significantly (p = 0.0018) correlated with vaccination failure (i.e. PD). It is noteworthy 
that the mfi values for TEM8 mRNA in PD patients were in line with those reported 
(>10 fold) in a study on serial gene expression analysis (SAGE) of purified 
endothelial cells from tumor-associated versus normal blood vessels (St. Croix B. et 
al., 2000). 
 
 
4.5 INDOLEAMINE 2,3-DIOXYGENASE (IDO) GENE EXPRESSION IN 
mDC 
A recent report (Wobser M. et al., 2007) demonstrated that enzyme indoleamine 2,3-
dioxygenase (IDO) is strongly up-regulated in human dendritic cells (DCs) from 
cancer patients upon in vitro maturation with IL-1, IL-6, TNF-α and PGE2 cocktail. 
IDO is supported to convey immunosoppressive effects by degrading the essential 
amino acid tryptophan, thereby down-regulating T-cell functions. Moreover, IDO 
expression in DC-based therapeutic vaccines in vivo, seem to attract or induce 
 32 
FoxP3+ T cells (Wobser M. et al., 2007). Indeed, IDO expression was detected both 
by standard RT-PCR and by real-time-PCR in our series of DCs from cancer patients 
and healthy donors. Although these analysis revealed marked intra- and 
interpersonal variation in IDO mRNA levels, all analyzed specimens, DC showed a 
strong mRNA up-regulation in upon PGE2 in vitro maturation over a time course of 
48h, (Fig. 9). However, our data do not significantly differ between DCs from PD and 
NP patients. 
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5. DISCUSSION 
 
 
The experimental therapeutic DC vaccination represents so far one of the best-
documented treatments for metastatic melanoma and renal cell cancer (RCC). The 
results from published trials phase I-II show that it is possible to induce antigen-
specific immunoresponses and obtain tumor regression in a subset of treated 
patients. However, despite occasional correlation between immunological and clinical 
responses, we don’t know whether the modest clinical responses we observed were 
caused by the vaccination or whether reflect patients with better prognosis capable of 
mounting immunoresponses. 
 
Although most efforts are dedicated to generate optimal DC vaccine by improving 
maturation stimuli, administration routes, and immunomonitoring, no study has been 
published to date to find predictive biological markers that select the patients with 
increased or decreased likelihood of responding to DC vaccine. 
This selection is important, because testing treatments that benefit only a subset of 
patients in an unselected population might obscure clinical important results. 
 
Arguably, the benefit of DCs vaccination is likely to differ in patients according to their 
tumor loading. Tumor takes the advance of several different strategies to interfere 
with DCs maturation and functions. Tumor-derived factors not only condition 
peripheral immune niches, but also the bone marrow and other hematopoietic 
organs. Indeed, recent studies suggest that advanced tumor might subvert expansion 
and differentiation of myelo-monocytes cells leading to abnormal myelopoiesis, with 
tumor-altered myeloid cells playing a critical role in tumor progression by promoting 
both tumor evasion from immune attack, and stimulation or amplification of tumor 
angiogenesis (McLean K., et al., 2008; Curiel T.J., et al., 2004; Priebe A., et al., 
2008; Melani C., et al. 2003). Having said that, it should be pointed out that most 
studies have focused on alterations in phenotype and function of DCs isolated 
directly from peripheral blood, while only few studies have described tumor-
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associated changes in monocyte-derived DCs. Thus, whether and how Mo-DCs 
generated from cancer patients differ from Mo-DCs from healthy individuals remain 
an open issue. 
 
A previous study (Pedersen A.E., et al. 2005), compared TNF-α + IL-1β + IL-6, and 
PGE2 matured DCs from breast cancer patients to similar DC from healthy donors. 
Patient-derived DC exhibited a more mature phenotype when compared with DC 
from healthy controls, particularly when comparing levels of CD40 and CD54 
expression, confirming the findings for other kinds of DC preparations in cancer 
patients (Della Bella S., et al. 2003; Kiertscher S.M., et al. 2000). Moreover DCs from 
breast cancer patients showed a significantly decreased allostimulatory capacity 
compared with DC of healthy controls. Thus, enhanced IL-10 production, IL-12 down 
regulation, and the low capacity for allogeneic stimulation are factors pointing 
towards a reduced functionality of the patient-derived DC (Pedersen A.E., et al. 
2005). The predictive value of these factors for the clinical applicability of the DC 
preparations is, however, uncertain. 
 
In the process of studying DCs vaccines, we become aware that TNF-α + IL-1β + IL-
6 + PGE2-maturated DCs either from cancer patients or healthy donors represent 
alternative activated DCs (M2-polarized) known to have tolerogenic properties and 
proangiogenic potential because of their overexpression of IDO mRNA and secretion 
of VEGF-A (Mantovani A., et al., 2002). In other words TNF-α + IL-1β + IL-6 + PGE2-
maturated DCs utilized as cancer vaccine might paradoxally, mimic tumor resident 
DCs suspected to promote neovascularization and tumor growth (Priebe A. et al., 
2008; Gottgried E., et al., 2007; St. Croix B., et al., 2000). Of interest, these DCs 
might display a mixed DC-endothelial cell phenotype and up modulate a number of 
tumor endothelial markers (TEMs1-9) (see above). 
 
Bearing this in mind, we set out to explore the possibility that monocyte-derived DCs 
utilized for therapeutic vaccination of cancer patients, could upregulate tumor-
endothelial marker 8 (TEM8) expression. Focusing on TEM8, its expression pattern 
is especially intriguing in that it is the only TEM characterized so far that shows no 
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detectable expression in either corpus luteum or wound healing, suggesting that this 
gene may be highly specific to tumor angiogenesis and not required for normal adult 
angiogenesis. Accordingly, although the biological function(s) of TEM8 remain 
essentially unknown, this anthrax receptor has been proposed as a marker of tumor 
progression and a potential therapeutic target for a variety of tumors (Xu Q., et al., 
2007; Duan H.F., et al., 2007). 
 
Here we report that TEM8 gene-protein expression levels in mDCs (evaluated by 
means of quantitative real-time RT-PCR and cytofluorimetric analysis, respectively) 
were clearly related to clinical outcome and immunoresponses in a case series of 17 
cancer patients who had taken part in DC phase I/II vaccination trials (2001-2005) for 
advanced melanoma (n = 13) and renal cell carcinoma (RCC; n = 4) (Ridolfi R., et al., 
2006). In the study, increased TEM8 mRNA and protein expression levels (mature 
(m) vs. immature (i) DCs) were observed in monocyte-cultured DCs generated from 
treatment-nonresponsive patients all but one with negative DTH. Conversely, DCs 
obtained from eight treatment-responsive patients, all DTH-positive, had TEM8 
expression values, not different from that found in healthy donor mDCs. Thus, mDC 
TEM8 expression levels, seems to identify (p = 0.0018) patients who could benefit 
from DC therapeutic vaccination. 
Of interest, neither VEGF-A production levels nor IDO gene overexpression in DCs 
had a clinical impact in this case series of patients. 
 
Are TEM8 expressing DCs “tolerogenic”, and therefore responsible for lack of 
therapeutic impact? or, Are the patients highly immunologically compromised, and 
TEM8 upregulation in their monocyte-derived DC is a correlate but not cause? 
 
We provide evidence that TEM8 up regulation is a direct consequence of PGE2 in the 
maturation cocktail. Moreover, when the response rates in clinical trials were 
evaluated, TNF-α + IL-1β + IL-6 + PGE2-maturated DCs did not seem to be less 
effective compared with DC maturated otherwise (McIlroy D., et al., 2003) Thus, is 
unlikely that TEM8 negative DCs induce better clinical responses. 
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It must be underlined that DC vaccines are customized in vitro artifacts (Nanda A., et 
al., 2004) developed from high variable mixtures of inflammatory monocytes of 
uncertain cell-lineage (i. e., CD14+CD16+ monocytes) (Nestle F.O., et al., 2005; 
Nagaraj S., et al. 2008), and immature (immunosuppressive) myeloid precursors 
(Arroyo J.C. et al. 2004; Nagaraj S. et al., 2008; Serafini P. et al. 2006). 
It is therefore conceivable that overexpression of TEM8 in mDCs from progressive 
patients is related to an overload of tumor “educated” myeloid-DC precursors. The 
fact that TEM8 overexpression is not detectable at the stage of iDCs may indicate 
that ”education” entails increased sensitivity to one or more components of the 
maturative cocktail. This would still held even if we had just compared TEM8 mDC of 
the responder vs. non-responder patients. Of interest, preliminary results from our 
laboratory, indicate that TNF-α + IL-1β + IL-6 + PGE2-maturated DCs from 3 out of 3 
patients with Policytemia Vera, with myeloprliferative disorders (e. g. Policytemia 
Vera) display TEM8 up modulation (results not shown). 
 
The information gained from the present study could contribute substantially to 
increasing response rates to DC immunotherapy by narrowing this high-cost and 
labour-intensive treatment to cancer patients whose in vitro mDCs display low levels 
of TEM8 expression. However, because of the relatively small number of patients 
involved and the retrospective nature of the study, the present results need to be 
confirmed in a prospective case series. 
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7. FIGURES 
 
 
Table I. Patient demographic, disease status, and pre-treatment characteristics 
(n = 17). Male/Female 12/5. Median age, 48 years (36-68). Yellow shading highlights 
renal cancer cell patients. PS (ECOG), performance status according to ECOG; 
Abbreviations: ln, lymph-node; lv, liver; st, soft tissues; kd, kidney; lg, lung; pv, pelvis; 
ag, adrenal glands; sk, skin; NT, no treatment; CT, chemotherapy; BIO, 
immunotherapy (Interferon, Interleukin 2); BIOCT, chemotherapy + immunotherapy. 
Patient ID Sex AGE P.S. (ECOG)
Site of evaluable 
disease
Pretreatments
35 G.D. M 46 0 ln NT
38 B.A. F 59 2 lv, st BIOCT, Locoreg CT
39 C.P. F 39 0 kd, st Locoreg CT
40 O.M. M 56 1 lg, st BIOCT
44 Z.S. M 62 1 ln BIO
46 R.P. M 56 0 lg, st CT
51 D.P. M 56 0 lg, st CT
52 L.B. F 39 2 pv, ln BIOCT
53 D.U. M 68 0 ln BIOCT
54 M.J.L. F 37 0 lg, kd, ln, st BIOCT
55 O.G. M 65 2 ag, ln, st BIOCT
56  R.M. M 48 0 ln, lg, lv BIO
57 M.R. F 38 0 ln BIOCT
58 De C.G. M 28 2 sk, lg, ln BIOCT
60 T.M. M 26 1 (2) sk, ln BIOCT
61 Di I. M 34 0 ln, sk NT
62 B.F. M 64 0 ln, sk NT
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Table II. Patients vaccination and clinical-immunological outcome. 
Yellow shading shows renal cancer cell patients. Abbreviation: LIS, autologous tumor 
cells lysate; KLH, keyhole limpet hemocyanin (KLH); DTH, delayed-type 
hypersensitivity test (best response after 4 or more vaccinations); na, not assessed; 
CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease; OS, overall survival; OS+, patients still alive. 
35 G.D. 16 12.6 (2.8 – 20.8) ++        +++ CR 8 34
38 B.A. 4 5.9 (3.7 – 12) -             - PD - 7
39 C.P. 6 7.8 (1.6 – 15) -           ++ PD - 20
40 O.M. 4 11.5 (10 – 21) -             - PD - 5
44 Z.S. 10 10 (6.6 - 17) -           + SD 6 12
46. R.P. 26 10 (8.2 - 11.6) +       ++ PR 30 36
51 D.P. 7 10 (9.6 - 10.8) -             - PD - 10
52 L.B. 4 12.5 (10 – 15.5) -             - PD - 3
53 D.U. 9 10 (5.3 - 10) +             + SD 10 36
54 M.J.L. 32 9.1 (2.2 – 11) +        +++ PR 22 39+
55 O.G. 5 10 (8.8 – 12.3) -             - PD - 3
56 R.M na -             - PD - 5
57 M.R. 4 9.2 (8 – 10) +         ++ SD 4 6
58De C.G. na -             - PD - 3
60 T.M. na -             - PD - 1
61 Di I. 10 10 (10 - 10.7) +         ++ CR 30+ 30+
62 B.F. 18 10 (10 - 10) ++         ++ PR 24 27+
OS    
(Months)
Pt.  ID N° VACC.
CLINICAL 
RESPONSE
RESPONSE 
and 
DURATION
 ADMINISTERED 
CELLS N° X 106 
(range)
DTH           
Response 
LIS / KLH
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Table III. DCs phenotype analysis. 
The table shows the percentage of dendritic cells with a particular surface marker. 3-
5 x 105 immature (iDCs), cytokine-cocktail (TNF-a, IL-1b, IL-6, PGE2) or matured 
(mDCs) dendritic cells from both melanoma and renal cell carcinoma patients (in 
black) and healthy donors (in blue) were incubated with appropriate fluorescein 
isothiocyanate or phycoerythrin-labeled monoclonal antibodies. iDCs and mDCs 
phenotypes were determined by single or two-color fluorescence analysis by a FACS 
Vantage flow cytometer. 
 
 
 
 
 
iDC median value 
(range)
mDC median value 
(range)
CD1a
27 (4.8-53)                   
35 (8.3-66)
3 (0-14)                             
39.3 (0-54)
CD14
2.6 (0-33)                           
3.6 (2-6)
3 (0-25)                              
1.3 (1-2)
CD80
6 (1-23)                            
21.6 (8-39)
43 (14.2-76)                    
86.6 (80-91)
CD86
29 (5.4-75)                      
13.6 (6-21)
80 (21.56-94)                  
95.3 (94-97)
DR
55 (8.2-76)                      
73.6 (64-83)
70.7 (20.18-92)              
75.6 (64-84)
CD83
2.08 (01-13)                          
1 (0-3)
46 (4.72-80)                       
95 (91-98)
CCR7
4 (2-5)                                    
7 (3-9)
86.5 (48-92)                    
79.6 (62-92)
CD33
37.6 (9-63)                      
38.3 (22-49)
11.6 (2-55)                            
2 (1-3)
CD11c
                                        
95.6 (43-98)
                                        
98.6 (96-99)
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Figure 1. DCs migration phenotype: CD83, CD80 and CCR7 expression (% 
positive cells). 
FACS analysis of CD83, CD80 and CCR7 expression on human immature and 
cytokine cocktail matured dendritic cells. 
 
 
 
 
 
 
 
 
 
 
 
Mature DC 
Immature DC 
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Figure 2. DCs angiogenic phenotype. 
ELISA test (Pierce Biotechnology): median values (pg/ml) of VEGF-A (165 and 121 
splicing forms) in supernatants of iDCs (1), DCs matured with the standard cocktail 
(2), with the PGE2-depleted cocktail (3), with LPS + PGE2 (4) or with TNF-a, IL-1b, IL-
6 and Poly I:C (5). 
 
 
 
 
 
 
 
                                       
Serum: 196.5 (22-420) pg/ml 
Plasma: nd (nd-11.8) pg/ml 
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Figure 3. TEM8 and CMG2 gene expression in myeloid DC 
(A) CMG2 and TEM8 expression in immature DC (iDCs) and PGE2-matured DC 
(mDCs) from cancer patients (n = 8). (B) CMG2 and TEM8 expression in mDCs from 
healthy donors (n = 3). (C) TEM8 expression in tumor cell lines: HeLa (1), MDA-MB-
231 (2), SK-BR3 (3), and ZR75-1 (4). B, blank. GAPDH expression was measured by 
RT-PCR as a positive amplification control in each experiment. 
Purified PCR products were visualized by agarose gel electrophoresis. 
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Figure 4. Quantitative-RT-PCR. 
Relative quantization of CMG2 to TEM8 gene transcripts in monocytes (Mo), 
immature DCs (iDC) and PGE2-matured DCs (mDC), evaluated as relative 
abundance of TEM8 and CMG2 compared to GAPDH. *p < 0.05. 
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Mo CMG2 vs TEM8 143 (65 - 230)
iDCs CMG2 vs TEM8 230 (50 - 461)
mDCs CMG2 vs TEM8 150 (60 - 278)
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Figure 5. Scatter plot of relative increase (mDCs vs. iDCs) of TEM8 and CMG2 
mRNA expression in cancer patients and healthy donors. Each dot represents a 
measurement for each subject: cancer patients (Pts. n = 17), healthy donors (Hds. n 
= 6). The results indicate the mean from three independent real-time RT-PCR 
reactions. Bars, mfi (range): TEM8 Hds = 2.7 (1.3 - 4); TEM8 Pts = 8.4 (0.3 - 30); 
CMG2 Hds = 1.95 (0.6 - 4.3); CMG2 Pts = 2.88 (0.12 - 8.34). 
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Figure 6. TEM8 mRNA expression by DCs activated by different maturative 
stimuli. 
(1) CKT + PGE2; (2) LPS+ TNFα; (3) LPS + PGE2. PGE2-depleted cocktail does not 
up-regulate TEM8 (results not shown). Pts, melanoma patients (ID; DC 39 and DC 
56). 
 
 
 
 
 
 
 
 
Pts #  56  39 
  (8.8) 
 (1.3)  (1.75) 
 (30) 
 (1.24) 
  (2.57) 
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Figure 7. Scatter plot of relative abundance of TEM8 and CMG2 mRNA (mDC 
vs. iDC) in cancer patients with different clinical outcome. 
PD, progressive disease; NP, non progressive patients. Bars, medium values 
(range): TEM8 PD = 12.88 (5 - 30); TEM8 NP = 1.97 (0.3 - 3.30); CMG2 PD = 2.88 
(0.12 - 8.34); CMG2 NP = 3.2 (0.4 - 8). 
 
 
 
0
4
8
12
16
20
24
28
32
36
40
[m
fi
]
  TEM8                                  CMG2 
    PD                  NP                 PD                 NP          
* (p = 0.0018) 
Fo
ld
 in
cr
ea
se
 o
f T
EM
8 
ex
pr
es
si
on
 
(12.88) 
(1.97) (2.88) 
(3.2) 
 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Cytofluorimetric analysis of TEM8 protein expression. 
PD patient (ID. 51; TEM8 mRNA mDC vs. iDC; mfi = 30); NP patient (ID. 61; TEM8 
mRNA mDC vs. iDC; mfi = 2.7). PD= 97% of mDC TEM8 positive cells; NP= 23% of 
mDC TEM8 positive cells. 
 
 
 
PD 
NP 
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Figure 9. IDO mRNA expression. (A) RT PCR-Steady state by DCs from different 
subjects. Pts, melanoma patients (ID; DC 39, DC 40 and DC 60); Hd; healthy donors; 
i, iDCs; m, mDCs.  (B) Quantitative-RT-PCR. 
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